Af­ter tar­get­ing strug­gling biotechs, Tang’s Con­cen­tra shifts gears with un­so­licit­ed bid for Lian­Bio

Tang Cap­i­tal Man­age­ment has made its fifth un­so­licit­ed ac­qui­si­tion bid of the year, this time for US-Chi­nese com­pa­ny Lian­Bio. The choice of tar­get marks a no­table change in strat­e­gy for the Cal­i­for­nia in­vest­ment group, which had opt­ed to propo­si­tion strug­gling ear­ly-stage biotechs in 2023.

Lian­Bio is in a rel­a­tive­ly strong po­si­tion com­pared with Tang’s pre­vi­ous tar­gets, which in­clude Atea Phar­ma­ceu­ti­cals, Jounce Ther­a­peu­tics, Rain On­col­o­gy and The­seus Phar­ma­ceu­ti­cals. Lian­Bio has sev­er­al part­nered prod­ucts on the mar­ket and has ben­e­fit­ed from a re­cent spate of clin­i­cal suc­cess­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER